🕐 When: 150 minutes per week, split however suits you. Five 30-minute blocks, three 50-minute sessions, or one long weekend ride all count. Morning sessions tend to deliver bigger cognitive gains the same day, and the BDNF spike is acute enough to double as a primer before a heavy deep-work block.

🎯 Specificity: Conversational pace. Heart rate around 60–70% of max, or RPE 3–4 out of 10. Incline walks, easy cycling, swimming, rowing, and hiking all qualify. If you're gasping for breath, ease off. The point is to stay aerobic so the mitochondrial signalling kicks in.

🚫 Friction removal: Stack it onto something you already do – take calls on a walking treadmill, cycle while watching a series, walk to coffees instead of taxiing. If 150 minutes feels far off, start with two 20-minute walks and build from there. Miss a day, resume the next.

📊 Tracking: Watch resting heart rate trend down over 6–8 weeks, HRV trend up, and VO₂ max climb if your wearable estimates it. Subjectively, expect cleaner mood, deeper sleep, and sharper afternoon focus within 3–4 weeks.

Discussion: A member's Ultrahuman Ring HRV jumped from a steady ~45ms baseline to ~90ms overnight, with no changes in training, sleep, or diet, and the new number has held since.

The verdict: Members flagged a likely Ultrahuman software update as the cause. One Zapien saw the same pattern weeks earlier and confirmed his Whoop showed no equivalent shift in HRV during the same window, pointing to an algorithm change rather than a physiological one. The recommended check is to triangulate against a second device (Whoop, Oura, Apple Watch, chest strap) before assuming the change is real.

Consider this: Wearable algorithms get silently updated all the time, and a baseline shift without warning is one of the most common artefacts. The fundamentals of HRV interpretation still hold: track trends over weeks, compare against your own baseline rather than population norms, and flag overnight step-changes for second-device verification. Our wearables and trackers directory is the place to start if you're considering adding a backup.

Discussion: Members wondered whether detailed protocols of the substances Enhanced Games athletes were running had been published, given the event's transparency claims.

The verdict: Only aggregate data has surfaced publicly. No individual protocols were released. Community estimates lean modest by performance-enhancement standards, particularly for the swimmers and runners, where excess muscle would impair mechanics. Best guesses landed around 150–300 mg testosterone per week, 100–200 mg nandrolone per week, 10–20 mg oxandrolone daily, and 1–4 IU HGH daily, with some athletes likely using Adderall, Modafinil, or low-dose EPO. One swimmer publicly noted he lowered his dose because added muscle disrupted his stroke.

Consider this: Every substance permitted was FDA-approved and prescribed by licensed physicians, which puts the conversation closer to clinical hormone optimisation than underground pharmacology. If you're curious about the same biomarker levers without a prescription pad, our testosterone training and sleep deep-dive covers what moves the needle naturally.

Discussion: A member shared a FirstWord Pharma writeup of Verve Therapeutics' updated Phase Ib Heart-2 results for VERVE-102, a one-time gene-editing infusion designed to lower LDL cholesterol permanently in patients at high cardiovascular risk.

The verdict: Interim data (presented at the European Atherosclerosis Society congress and published in the NEJM) showed VERVE-102 reduced PCSK9 protein by up to 88% and LDL-C by up to 62% after a single infusion, with effects tracked as long as 18 months so far. The mechanism is base-editing: a permanent, targeted edit to the PCSK9 gene in liver cells. For context, current PCSK9 inhibitors like Repatha and Praluent require ongoing injections every 2–4 weeks for life.

Consider this: This is still Phase Ib, so commercial availability is years out. The bigger signal is the direction of travel: "one-and-done" cardiovascular prevention is becoming a real category, especially for people genetically prone to high LDL. In the meantime, our Blood Testing Guide covers which lipid markers (ApoB, Lp(a), oxidised LDL) actually predict cardiovascular risk – useful baseline data whether or not therapies like this end up in your future.